<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Sulfasalazine and 5-aminosalicylates in the treatment of inflammatory bowel disease</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Sulfasalazine and 5-aminosalicylates in the treatment of inflammatory bowel disease</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Sulfasalazine and 5-aminosalicylates in the treatment of inflammatory bowel disease</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Adam S Cheifetz, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Garret J Cullen, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sunanda V Kane, MD, MSPH</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kristen M Robson, MD, MBA, FACG</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Dec 08, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Salicylazosulfapyridine (<a class="drug drug_general" data-topicid="9963" href="/d/drug information/9963.html" rel="external">sulfasalazine</a>) was originally proposed as a treatment for rheumatoid arthritis. It was subsequently discovered that sulfasalazine was also efficacious in treating inflammatory bowel disease, particularly ulcerative colitis. The 5-aminosalicylic acid (5-ASA) medications were developed because many patients were intolerant of or allergic to sulfasalazine.</p><p>This topic will review the pharmacology of <a class="drug drug_general" data-topicid="9963" href="/d/drug information/9963.html" rel="external">sulfasalazine</a> and 5-ASAs, mechanism of action in inflammatory bowel disease, and side effects. The role of sulfasalazine and 5-ASAs in the treatment of inflammatory bowel disease and rheumatoid arthritis are discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/4069.html" rel="external">"Overview of the medical management of mild (low risk) Crohn disease in adults"</a> and  <a class="medical medical_review" href="/d/html/4051.html" rel="external">"Medical management of low-risk adult patients with mild to moderate ulcerative colitis"</a> and  <a class="medical medical_review" href="/d/html/4068.html" rel="external">"Management of the hospitalized adult patient with severe ulcerative colitis"</a> and  <a class="medical medical_review" href="/d/html/7524.html" rel="external">"Sulfasalazine: Pharmacology, administration, and adverse effects in the treatment of rheumatoid arthritis"</a>.)</p><p class="headingAnchor" id="H194952450"><span class="h1">PHARMACOLOGY</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9963" href="/d/drug information/9963.html" rel="external">Sulfasalazine</a> is a prodrug composed of 5-aminosalicylic acid (5-ASA) linked to sulfapyridine through an azo bond (<a class="graphic graphic_figure graphicRef76617" href="/d/graphic/76617.html" rel="external">figure 1</a>). Sulfasalazine is partially absorbed in the jejunum after oral ingestion. The remainder passes into the colon, where it is reduced by coliform bacterial enzyme, azoreductase, to sulfapyridine and 5-ASA [<a href="#rid1">1</a>]. </p><p>The majority of absorbed <a class="drug drug_general" data-topicid="9963" href="/d/drug information/9963.html" rel="external">sulfasalazine</a> is excreted into bile; only a small fraction is excreted in the urine. 5-ASA is poorly absorbed from the colon and is largely excreted in the stool. Sulfapyridine is rapidly absorbed from the colon, metabolized by the liver, and excreted in the urine with only small amounts remaining in the stool.</p><p>5-ASA is primarily responsible for the efficacy of <a class="drug drug_general" data-topicid="9963" href="/d/drug information/9963.html" rel="external">sulfasalazine</a>, while sulfapyridine accounts for many of its side effects. Unconjugated 5-ASA (<a class="drug drug_general" data-topicid="9614" href="/d/drug information/9614.html" rel="external">mesalamine</a>) does not have the side effects associated with sulfapyridine, but is rapidly absorbed in the jejunum, allowing only 20 percent to reach the terminal ileum and colon. Therefore, a number of 5-ASA compounds have been developed to prevent absorption of 5-ASA in the proximal gastrointestinal tract, and thereby increase delivery to the colon (<a class="graphic graphic_table graphicRef86818" href="/d/graphic/86818.html" rel="external">table 1</a>). </p><p class="headingAnchor" id="H194953227"><span class="h2">5-ASA formulations</span><span class="headingEndMark"> — </span>Oral 5-ASA formulations differ in their mode of delivery of the active drug to the colon (<a class="graphic graphic_table graphicRef86818" href="/d/graphic/86818.html" rel="external">table 1</a>) [<a href="#rid2">2</a>]. The systemic absorption and efficacy are comparable to <a class="drug drug_general" data-topicid="9963" href="/d/drug information/9963.html" rel="external">sulfasalazine</a>, and 5-ASAs are better tolerated [<a href="#rid3">3,4</a>]. There does not appear to be any difference in efficacy or safety between the various formulations of oral 5-ASAs [<a href="#rid5">5</a>]. Therefore, the choice of oral 5-ASA for treatment of inflammatory bowel disease should be based on the indication (eg, induction or maintenance of remission in ulcerative colitis), disease location, patient preference, ability to comply with the prescribed dosing regimen, cost, and availability of the drug. (See  <a class="medical medical_review" href="/d/html/4051.html" rel="external">"Medical management of low-risk adult patients with mild to moderate ulcerative colitis", section on 'Left-sided or extensive colitis'</a>.)</p><p>The following oral 5-ASA formulations have been developed:</p><p class="bulletIndent1"><span class="glyph">●</span>Dimerization of 5-ASA has been used to develop prodrug formulations <a class="drug drug_general" data-topicid="9717" href="/d/drug information/9717.html" rel="external">olsalazine</a> and <a class="drug drug_general" data-topicid="8713" href="/d/drug information/8713.html" rel="external">balsalazide</a>. Olsalazine consists of two 5-ASAs joined together with an azo bond, while balsalazide consists of one 5-ASA linked to an inert unabsorbed carrier molecule. As colonic bacteria are required to cleave the azo bond and release the 5-ASA moiety, these formulations are active only in the colon. Olsalazine is administered orally twice daily. Balsalazide is available in two formulations, which are administered orally usually two to three times a day.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Delayed- and controlled-release <a class="drug drug_general" data-topicid="9614" href="/d/drug information/9614.html" rel="external">mesalamine</a> formulations consist of single 5-ASA molecules enclosed within an enteric coat or a semipermeable membrane that resists gastric breakdown.</p><p></p><p class="bulletIndent1">In delayed-release formulations, the release of 5-ASA is pH-dependent. The acrylic-base resin dissolves at a pH ≥7, delivering 10 to 15 percent of 5-ASA to the terminal ileum and remainder in the colon. In controlled-release formulations, the release of 5-ASA is time-dependent and independent of pH. The ethylcellulose coating serves as a semipermeable membrane that releases 30 to 40 percent of 5-ASA in the duodenum and continues release throughout the small intestine and colon. Delayed-release <a class="drug drug_general" data-topicid="9614" href="/d/drug information/9614.html" rel="external">mesalamine</a> can be administered orally one to three times daily and controlled-release mesalamine is typically administered orally four times daily. However, studies suggest that some formulations can be taken once daily [<a href="#rid5">5-8</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Extended-release forms of <a class="drug drug_general" data-topicid="9614" href="/d/drug information/9614.html" rel="external">mesalamine</a> contain mesalamine granules encased in microcrystalline cellulose that delivers mesalamine to the colon via a proprietary extended-release mechanism. The outer coating dissolves at a pH ≥6 in the distal ileum. Upon release, the granules swell to delay transit through the colon and provide gradual, extended release of 5-ASA throughout the colon, allowing for once daily dosing. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9614" href="/d/drug information/9614.html" rel="external">Mesalamine</a> pellets consist of 5-ASA microgranules with acrylic resin or ethylcellulose. Pellets pass unaltered to the distal small bowel, where they begin to release 5-ASA at pH &gt;6.0 and then continue to release 5-ASA throughout the colon. Mesalamine micropellets are administered orally once to four times daily and have the advantage that they can be sprinkled on food.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The Multi-Matrix System (MMX) <a class="drug drug_general" data-topicid="9614" href="/d/drug information/9614.html" rel="external">mesalamine</a> formulation consists of a pH-dependent coating to delay drug release until the terminal ileum and lipophilic and hydrophilic matrix. The outer coating dissolves at pH 7 in the distal ileum, exposing the matrix. The matrix expands when exposed to luminal fluid to form a gel that gradually releases 5-ASA in the ileum and colon. MMX-mesalamine has a comparable efficacy and safety profile to other 5-ASA formulations, and has the advantage of once daily dosing and possibly improved compliance [<a href="#rid9">9-13</a>].</p><p></p><p>A number of topical formulations of 5-ASA are also available and are discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/4051.html" rel="external">"Medical management of low-risk adult patients with mild to moderate ulcerative colitis"</a>.)</p><p class="headingAnchor" id="H194952457"><span class="h1">MECHANISM OF ACTION</span><span class="headingEndMark"> — </span>Although the precise mechanism responsible for the clinical efficacy of 5-aminosalicylic acid (5-ASA) compounds is not known, they are thought to act topically. In vitro investigations have identified many antiinflammatory and immunosuppressive properties of 5-ASA, suggesting a multifactorial basis of therapeutic action. The following mechanisms have been proposed.</p><p class="headingAnchor" id="H382461902"><span class="h2">Inhibition of cytokine synthesis</span><span class="headingEndMark"> — </span>Downregulation of peroxisome proliferator activated receptor-gamma (PPAR-gamma) has been shown to be involved in inflammation in patients with inflammatory bowel disease [<a href="#rid14">14,15</a>]. Enhanced mucosal production of proinflammatory cytokines has also been correlated with active inflammatory bowel disease [<a href="#rid16">16</a>]. 5-ASA medications may exert their anti-inflammatory effect by inducing PPAR-gamma gene expression and that of its target genes and suppressing the activation of cytokine NFκB and toll-like receptors (TLRs) [<a href="#rid17">17</a>]. 5-ASAs, and to some extent <a class="drug drug_general" data-topicid="9963" href="/d/drug information/9963.html" rel="external">sulfasalazine</a>, also inhibit the biologic functions of the proinflammatory cytokines interleukin 1 (IL-1), tumor necrosis factor alpha (TNFa), IL-2, IL-8, and NF kB [<a href="#rid18">18-20</a>]. (See  <a class="medical medical_review" href="/d/html/3985.html" rel="external">"Toll-like receptors: Roles in disease and therapy"</a>.)</p><p class="headingAnchor" id="H194952464"><span class="h2">Inhibition of prostaglandin and leukotriene synthesis</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9963" href="/d/drug information/9963.html" rel="external">Sulfasalazine</a> and 5-ASA inhibit cyclooxygenase and lipoxygenase enzymes in arachidonic acid metabolism, thereby preventing formation of proinflammatory prostaglandins and leukotrienes (eg, LTB4) [<a href="#rid21">21-25</a>]. Support for this proposed mechanism of action in inflammatory bowel disease was derived from preliminary trials with lipoxygenase inhibitors [<a href="#rid26">26,27</a>]. Although subsequent randomized trials have not demonstrated a clinical benefit in patients with inflammatory bowel disease, it is unclear if this lack of efficacy was due to incomplete enzyme inhibition [<a href="#rid28">28</a>].</p><p class="headingAnchor" id="H194952471"><span class="h2">Free radical scavenging</span><span class="headingEndMark"> — </span>Reactive metabolites of oxygen and nitrogen mediate tissue injury via oxidation of cellular proteins. 5-ASA is a potent free radical scavenger and antioxidant at the concentrations achieved within the intestinal mucosa [<a href="#rid29">29-31</a>]. The enhanced production of oxidized 5-ASA metabolites in the mucosa and stool of patients treated with <a class="drug drug_general" data-topicid="9963" href="/d/drug information/9963.html" rel="external">sulfasalazine</a> lends support to free radical scavenging activity as a mechanism of action [<a href="#rid30">30</a>].</p><p>5-ASA may also exhibit antioxidant activity by another mechanism. In one study, for example, it augmented the thermal induction of intestinal epithelial heat shock protein (hsp72) expression, an effect that was accompanied by increased cellular protection against oxidant injury [<a href="#rid32">32</a>].</p><p class="headingAnchor" id="H194952478"><span class="h2">Immunosuppressive activity</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9963" href="/d/drug information/9963.html" rel="external">Sulfasalazine</a> and 5-ASA possess immunosuppressive activity. They block lymphocyte DNA synthesis and cell cycle progression in vitro, thereby preventing clonal expansion of potential pathogenic T-cell and B-cell populations [<a href="#rid33">33,34</a>]. In addition, 5-ASA prevents the accumulation of the early T-cell activation gene for IL-2 [<a href="#rid33">33</a>]. Thus, 5-ASA inhibits both T-cell proliferation and subsequent activation and differentiation.</p><p class="headingAnchor" id="H194952485"><span class="h2">Impairment of white cell adhesion and function</span><span class="headingEndMark"> — </span>Polymorphonuclear leukocyte and macrophage functions, including chemotaxis, phagocytosis, and adhesion, which are crucial to acute inflammatory processes, are also markedly inhibited by <a class="drug drug_general" data-topicid="9963" href="/d/drug information/9963.html" rel="external">sulfasalazine</a> and 5-ASA in vitro [<a href="#rid35">35-37</a>]. The reduction in leukocyte adhesion appears to be mediated via inhibition of the enzyme amino-imidazolecarboxamidoribonucleotide (AICAR) transformylase. This leads to the accumulation of AICAR, which results in an increase in adenosine release at inflamed sites [<a href="#rid38">38</a>]. Adenosine reduces local inflammation by inhibiting leukocyte adhesion to endothelial cells.</p><p class="headingAnchor" id="H11"><span class="h1">SIDE EFFECTS</span><span class="headingEndMark"> — </span>Side effects can occur with both <a class="drug drug_general" data-topicid="9963" href="/d/drug information/9963.html" rel="external">sulfasalazine</a> and 5-ASA (<a class="graphic graphic_table graphicRef64059" href="/d/graphic/64059.html" rel="external">table 2</a>), but are more common with sulfasalazine.</p><p class="headingAnchor" id="H12"><span class="h2">Sulfasalazine</span><span class="headingEndMark"> — </span>Approximately 20 to 25 percent of patients discontinue <a class="drug drug_general" data-topicid="9963" href="/d/drug information/9963.html" rel="external">sulfasalazine</a> due to side effects [<a href="#rid39">39</a>]. The side effects associated with sulfasalazine are either idiosyncratic (eg, hypersensitivity or immune-related) or dose-related [<a href="#rid40">40</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Idiosyncratic effects include skin rash that may be severe (eg, exfoliative dermatitis), hepatitis, pancreatitis, pneumonitis, agranulocytosis, and aplastic anemia [<a href="#rid41">41</a>]. When such reactions occur, the drug should be immediately stopped, and the patient should not be rechallenged with <a class="drug drug_general" data-topicid="9963" href="/d/drug information/9963.html" rel="external">sulfasalazine</a>.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Dose-related side effects include gastrointestinal, central nervous system, and mild hematologic toxicities. Symptoms and laboratory findings of such involvement include anorexia, headache, nausea, vomiting, dyspepsia, diarrhea, leukopenia, hemolytic anemia, and a megaloblastic anemia. These side effects may resolve with dose reduction.</p><p></p><p>The most common side effects of <a class="drug drug_general" data-topicid="9963" href="/d/drug information/9963.html" rel="external">sulfasalazine</a> include nausea, headache, fever, and rash (<a class="graphic graphic_table graphicRef64059" href="/d/graphic/64059.html" rel="external">table 2</a>). Male patients treated with sulfasalazine may experience oligospermia and infertility that are reversible with drug discontinuation [<a href="#rid42">42</a>].</p><p>Although most episodes of leukopenia are mild and transient, life-threatening agranulocytosis is a rare side effect of <a class="drug drug_general" data-topicid="9963" href="/d/drug information/9963.html" rel="external">sulfasalazine</a> [<a href="#rid43">43,44</a>]. Agranulocytosis typically occurs within the first three months of therapy and is almost invariably accompanied by fever and rash. Agranulocytosis may be fatal, although bone marrow recovery occurs in the majority of patients within one to two weeks of drug discontinuation. (See  <a class="medical medical_review" href="/d/html/8374.html" rel="external">"Drug-induced neutropenia and agranulocytosis", section on 'Sulfasalazine'</a>.)</p><p>Complete blood count, renal function tests, and liver biochemical tests should be performed at the initiation of therapy. Subsequent monitoring should be performed every one to two weeks during the first month, then monthly for the next three months, and every three months thereafter [<a href="#rid42">42</a>].</p><p><a class="drug drug_general" data-topicid="9963" href="/d/drug information/9963.html" rel="external">Sulfasalazine</a> inhibits transport of reduced <a class="drug drug_general" data-topicid="8475" href="/d/drug information/8475.html" rel="external">folic acid</a> across cell membranes in an in vitro model [<a href="#rid45">45</a>]. This effect could cause intracellular folate deficiency and contribute to the megaloblastic anemia associated with sulfasalazine therapy. Folic acid supplementation at a dose of 1 mg daily should therefore be recommended in all patients on sulfasalazine. (See  <a class="medical medical_review" href="/d/html/4051.html" rel="external">"Medical management of low-risk adult patients with mild to moderate ulcerative colitis", section on 'Left-sided or extensive colitis'</a>.)</p><p class="headingAnchor" id="H13"><span class="h2">5-aminosalicylic acid (5-ASA)</span><span class="headingEndMark"> — </span>The 5-ASA compounds are generally better tolerated than <a class="drug drug_general" data-topicid="9963" href="/d/drug information/9963.html" rel="external">sulfasalazine</a>. Headache, nausea, and abdominal pain are the common side effects with 5-ASA medications (<a class="graphic graphic_table graphicRef64059" href="/d/graphic/64059.html" rel="external">table 2</a>) [<a href="#rid46">46</a>]. Although most patients who are intolerant of sulfasalazine will tolerate 5-ASA, approximately 10 percent of patients will experience similar side effects and are unable to tolerate oral 5-ASAs [<a href="#rid47">47</a>].</p><p>Mild watery diarrhea can occur in up to 8 percent of patients on oral 5-ASA preparations. Diarrhea occurs at the initiation of therapy and usually resolves in four to eight weeks due to the ability of the colon to adapt to an elevated fluid load secondary to increased absorption. However, <a class="drug drug_general" data-topicid="9717" href="/d/drug information/9717.html" rel="external">olsalazine</a> and <a class="drug drug_general" data-topicid="8713" href="/d/drug information/8713.html" rel="external">balsalazide</a> can cause persistent watery diarrhea in up to 15 percent of patients by promoting ileal secretion of water and electrolytes. In such cases, olsalazine or balsalazide should be switched to another 5-ASA preparation [<a href="#rid48">48</a>].</p><p>Approximately 3 percent of patients on oral 5-ASAs have a paradoxical worsening of their colitis symptoms with diarrhea, bleeding, acute abdominal pain, and in some cases fever, headache, and rash. These patients should be considered allergic to 5-ASAs, and 5-ASAs should no longer be used.</p><p>Pancreatitis, pericarditis, skin rash that may be severe (eg, toxic epidermal necrolysis), and pneumonitis have been reported due to hypersensitivity reactions to 5-ASAs. In such cases, the drug should be discontinued and should not be resumed as these side effects are likely to recur [<a href="#rid49">49-52</a>]. </p><p>Nephrotoxicity is rare in patients on 5-ASA medications with a mean incidence of 0.3 percent per person-year [<a href="#rid53">53</a>]. In most cases, renal failure is caused by an acute or chronic interstitial nephritis, which is idiosyncratic and unrelated to the 5-ASA formulation and dose [<a href="#rid54">54</a>]. Renal function should be monitored, though there is no consensus on how frequently this needs to occur. We recommend serum blood urea nitrogen and creatinine be measured at six weeks, six months, and 12 months after initiation of 5-ASA therapy and then annually [<a href="#rid53">53</a>]. These drugs should be used cautiously in patients with underlying renal insufficiency with careful monitoring of renal function [<a href="#rid55">55</a>]. (See  <a class="medical medical_review" href="/d/html/4051.html" rel="external">"Medical management of low-risk adult patients with mild to moderate ulcerative colitis", section on 'Laboratory monitoring'</a> and  <a class="medical medical_review" href="/d/html/7234.html" rel="external">"Clinical manifestations and diagnosis of acute interstitial nephritis"</a>.) .</p><p class="headingAnchor" id="H18732229"><span class="h1">SPECIAL POPULATIONS</span></p><p class="headingAnchor" id="H7496204"><span class="h2">Pregnancy</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9963" href="/d/drug information/9963.html" rel="external">Sulfasalazine</a> can be continued safely throughout pregnancy and nursing. <a class="drug drug_general" data-topicid="8475" href="/d/drug information/8475.html" rel="external">Folic acid</a> 2 mg daily is recommended in pregnant women due to the effect of sulfasalazine on folate metabolism. Non-enteric coated 5-aminosalicylic acid (5-ASA) and topical 5-ASAs also appear to be safe in pregnancy (<a class="graphic graphic_table graphicRef86818" href="/d/graphic/86818.html" rel="external">table 1</a>) [<a href="#rid56">56,57</a>]. The use of sulfasalazine and 5-ASAs in pregnancy and nursing is discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/4083.html" rel="external">"Fertility, pregnancy, and nursing in inflammatory bowel disease"</a>.)</p><p class="headingAnchor" id="H2785142065"><span class="h2">Patients with COVID-19</span><span class="headingEndMark"> — </span>Issues related to SARS-CoV-2 infection in patients with IBD, including medication adjustments in the setting of COVID-19, are discussed separately. (See  <a class="medical medical_review" href="/d/html/127965.html" rel="external">"COVID-19: Issues related to gastrointestinal disease in adults"</a>.)</p><p class="headingAnchor" id="H3170126119"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/109937.html" rel="external">"Society guideline links: Ulcerative colitis in adults"</a> and  <a class="medical medical_society_guidelines" href="/d/html/109856.html" rel="external">"Society guideline links: Crohn disease in adults"</a>.)</p><p class="headingAnchor" id="H590170186"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/d/html/15613.html" rel="external">"Patient education: Ulcerative colitis in adults (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/d/html/1991.html" rel="external">"Patient education: Ulcerative colitis (Beyond the Basics)"</a> and  <a class="medical medical_patient" href="/d/html/2018.html" rel="external">"Patient education: Sulfasalazine and the 5-aminosalicylates (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H17"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pharmacology</strong> – <a class="drug drug_general" data-topicid="9963" href="/d/drug information/9963.html" rel="external">Sulfasalazine</a> is a prodrug composed of 5-aminosalicylic acid (5-ASA) linked to sulfapyridine through an azo bond. 5-ASA is primarily responsible for the efficacy of sulfasalazine, while sulfapyridine accounts for many of its side effects. (See <a class="local">'Pharmacology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>5-ASA formulations</strong> – Since orally ingested unconjugated 5-ASA (<a class="drug drug_general" data-topicid="9614" href="/d/drug information/9614.html" rel="external">mesalamine</a>) undergoes rapid absorption in the jejunum, various formulations have been developed to prevent proximal absorption of 5-ASA and increase bioavailability in the distal small bowel and colon (<a class="graphic graphic_table graphicRef86818" href="/d/graphic/86818.html" rel="external">table 1</a>). (See <a class="local">'5-ASA formulations'</a> above.)</p><p></p><p class="bulletIndent1">5-ASA preparations are as effective as <a class="drug drug_general" data-topicid="9963" href="/d/drug information/9963.html" rel="external">sulfasalazine</a> in the treatment of inflammatory bowel disease and are better tolerated. Therefore, initial treatment choice should be based on the indication (eg, induction or maintenance of remission in ulcerative colitis), disease location, patient preference, ability to comply with the prescribed dosing regimen, cost, and availability of the drug. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mechanism of action</strong> – 5-ASAs have antiinflammatory properties and are thought to act topically. Several different mechanisms of action have been proposed, including inhibition of cytokine, prostaglandin, and leukotriene synthesis, free radical scavenging, immunosuppressive activity, and impairment of white cell adhesion and function. (See <a class="local">'Mechanism of action'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adverse effects</strong> – The 5-ASA compounds are generally better tolerated than <a class="drug drug_general" data-topicid="9963" href="/d/drug information/9963.html" rel="external">sulfasalazine</a>. Common side effects of sulfasalazine and 5-ASAs include nausea and headache. Sulfasalazine has been associated with reversible male infertility and, rarely, agranulocytosis. Transient mild watery diarrhea can occur in patients on all oral 5-ASA preparations. However, <a class="drug drug_general" data-topicid="9717" href="/d/drug information/9717.html" rel="external">olsalazine</a> and <a class="drug drug_general" data-topicid="8713" href="/d/drug information/8713.html" rel="external">balsalazide</a> can cause persistent watery diarrhea. Approximately 3 percent of patients on oral 5-ASA have a paradoxical worsening of their colitis symptoms with diarrhea, bleeding, and acute abdominal pain (<a class="graphic graphic_table graphicRef64059" href="/d/graphic/64059.html" rel="external">table 2</a>). These patients should be considered allergic to 5-ASAs, and 5-ASAs should no longer be used. (See <a class="local">'Side effects'</a> above.)</p><p></p><p class="headingAnchor" id="H3932686401"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Paul Rutgeerts, MD (deceased), who contributed as a section editor for UpToDate in Gastroenterology.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Peppercorn MA, Goldman P. The role of intestinal bacteria in the metabolism of salicylazosulfapyridine. J Pharmacol Exp Ther 1972; 181:555.</a></li><li><a class="nounderline abstract_t">Ordás I, Eckmann L, Talamini M, et al. Ulcerative colitis. Lancet 2012; 380:1606.</a></li><li><a class="nounderline abstract_t">Sandborn WJ, Hanauer SB. Systematic review: the pharmacokinetic profiles of oral mesalazine formulations and mesalazine pro-drugs used in the management of ulcerative colitis. Aliment Pharmacol Ther 2003; 17:29.</a></li><li><a class="nounderline abstract_t">Sutherland L, Macdonald JK. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 2006; :CD000543.</a></li><li><a class="nounderline abstract_t">Feagan BG, Macdonald JK. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev 2012; 10:CD000544.</a></li><li><a class="nounderline abstract_t">Zhu Y, Tang RK, Zhao P, et al. Can oral 5-aminosalicylic acid be administered once daily in the treatment of mild-to-moderate ulcerative colitis? A meta-analysis of randomized-controlled trials. Eur J Gastroenterol Hepatol 2012; 24:487.</a></li><li><a class="nounderline abstract_t">Tong JL, Huang ML, Xu XT, et al. Once-daily versus multiple-daily mesalamine for patients with ulcerative colitis: a meta-analysis. J Dig Dis 2012; 13:200.</a></li><li><a class="nounderline abstract_t">Ford AC, Khan KJ, Sandborn WJ, et al. Once-daily dosing vs. conventional dosing schedule of mesalamine and relapse of quiescent ulcerative colitis: systematic review and meta-analysis. Am J Gastroenterol 2011; 106:2070.</a></li><li><a class="nounderline abstract_t">D'Haens G, Hommes D, Engels L, et al. Once daily MMX mesalazine for the treatment of mild-to-moderate ulcerative colitis: a phase II, dose-ranging study. Aliment Pharmacol Ther 2006; 24:1087.</a></li><li><a class="nounderline abstract_t">Lichtenstein GR, Kamm MA, Boddu P, et al. Effect of once- or twice-daily MMX mesalamine (SPD476) for the induction of remission of mild to moderately active ulcerative colitis. Clin Gastroenterol Hepatol 2007; 5:95.</a></li><li><a class="nounderline abstract_t">Kamm MA, Sandborn WJ, Gassull M, et al. Once-daily, high-concentration MMX mesalamine in active ulcerative colitis. Gastroenterology 2007; 132:66.</a></li><li><a class="nounderline abstract_t">Sandborn WJ, Kamm MA, Lichtenstein GR, et al. MMX Multi Matrix System mesalazine for the induction of remission in patients with mild-to-moderate ulcerative colitis: a combined analysis of two randomized, double-blind, placebo-controlled trials. Aliment Pharmacol Ther 2007; 26:205.</a></li><li><a class="nounderline abstract_t">Kane S, Huo D, Magnanti K. A pilot feasibility study of once daily versus conventional dosing mesalamine for maintenance of ulcerative colitis. Clin Gastroenterol Hepatol 2003; 1:170.</a></li><li><a class="nounderline abstract_t">Peyrin-Biroulet L, Beisner J, Wang G, et al. Peroxisome proliferator-activated receptor gamma activation is required for maintenance of innate antimicrobial immunity in the colon. Proc Natl Acad Sci U S A 2010; 107:8772.</a></li><li><a class="nounderline abstract_t">Yamamoto-Furusho JK, Peñaloza-Coronel A, Sánchez-Muñoz F, et al. Peroxisome proliferator-activated receptor-gamma (PPAR-γ) expression is downregulated in patients with active ulcerative colitis. Inflamm Bowel Dis 2011; 17:680.</a></li><li class="breakAll">Fiocchi C, Podolsky DK. Cytokines and growth factors in inflammatory bowel disease. In: Inflammatory Bowel Disease, 4th ed, Kirsner JB, Shorter RG (Eds), Lea &amp; Febriger, Philadelphia 1995. p.252.</li><li><a class="nounderline abstract_t">Rousseaux C, Lefebvre B, Dubuquoy L, et al. Intestinal antiinflammatory effect of 5-aminosalicylic acid is dependent on peroxisome proliferator-activated receptor-gamma. J Exp Med 2005; 201:1205.</a></li><li><a class="nounderline abstract_t">Cominelli F, Zipser RD, Dinarello CA. Sulfasalazine inhibits cytokine production in human mononuclear cells: A novel anti-inflammatory mechanism. Gastroenterology 1992; 96:A96.</a></li><li><a class="nounderline abstract_t">Shanahan F, Niederlehner A, Carramanzana N, Anton P. Sulfasalazine inhibits the binding of TNF alpha to its receptor. Immunopharmacology 1990; 20:217.</a></li><li><a class="nounderline abstract_t">Bantel H, Berg C, Vieth M, et al. Mesalazine inhibits activation of transcription factor NF-kappaB in inflamed mucosa of patients with ulcerative colitis. Am J Gastroenterol 2000; 95:3452.</a></li><li><a class="nounderline abstract_t">Sharon P, Ligumsky M, Rachmilewitz D, Zor U. Role of prostaglandins in ulcerative colitis. Enhanced production during active disease and inhibition by sulfasalazine. Gastroenterology 1978; 75:638.</a></li><li><a class="nounderline abstract_t">Hawkey CJ, Boughton-Smith NK, Whittle BJ. Modulation of human colonic arachidonic acid metabolism by sulfasalazine. Dig Dis Sci 1985; 30:1161.</a></li><li><a class="nounderline abstract_t">Ligumsky M, Karmeli F, Sharon P, et al. Enhanced thromboxane A2 and prostacyclin production by cultured rectal mucosa in ulcerative colitis and its inhibition by steroids and sulfasalazine. Gastroenterology 1981; 81:444.</a></li><li><a class="nounderline abstract_t">Miller DK, Gillard JW, Vickers PJ, et al. Identification and isolation of a membrane protein necessary for leukotriene production. Nature 1990; 343:278.</a></li><li><a class="nounderline abstract_t">Stenson WF, Lobos E. Sulfasalazine inhibits the synthesis of chemotactic lipids by neutrophils. J Clin Invest 1982; 69:494.</a></li><li><a class="nounderline abstract_t">Zingarelli B, Squadrito F, Graziani P, et al. Effects of zileuton, a new 5-lipoxygenase inhibitor, in experimentally induced colitis in rats. Agents Actions 1993; 39:150.</a></li><li><a class="nounderline abstract_t">Bell RL, Lanni C, Malo PE, et al. Preclinical and clinical activity of zileuton and A-78773. Ann N Y Acad Sci 1993; 696:205.</a></li><li><a class="nounderline abstract_t">Rask-Madsen J, Bukhave K, Laursen LS, Lauritsen K. 5-Lipoxygenase inhibitors for the treatment of inflammatory bowel disease. Agents Actions 1992; Spec No:C37.</a></li><li><a class="nounderline abstract_t">Craven PA, Pfanstiel J, Saito R, DeRubertis FR. Actions of sulfasalazine and 5-aminosalicylic acid as reactive oxygen scavengers in the suppression of bile acid-induced increases in colonic epithelial cell loss and proliferative activity. Gastroenterology 1987; 92:1998.</a></li><li><a class="nounderline abstract_t">Ahnfelt-Rønne I, Nielsen OH, Christensen A, et al. Clinical evidence supporting the radical scavenger mechanism of 5-aminosalicylic acid. Gastroenterology 1990; 98:1162.</a></li><li><a class="nounderline abstract_t">Grisham MB, Granger DN. 5-Aminosalicylic acid concentration in mucosal interstitium of cat small and large intestine. Dig Dis Sci 1989; 34:573.</a></li><li><a class="nounderline abstract_t">Burress GC, Musch MW, Jurivich DA, et al. Effects of mesalamine on the hsp72 stress response in rat IEC-18 intestinal epithelial cells. Gastroenterology 1997; 113:1474.</a></li><li><a class="nounderline abstract_t">Stevens C, Lipman M, Fabry S, et al. 5-Aminosalicylic acid abrogates T-cell proliferation by blocking interleukin-2 production in peripheral blood mononuclear cells. J Pharmacol Exp Ther 1995; 272:399.</a></li><li><a class="nounderline abstract_t">MacDermott RP, Schloemann SR, Bertovich MJ, et al. Inhibition of antibody secretion by 5-aminosalicylic acid. Gastroenterology 1989; 96:442.</a></li><li><a class="nounderline abstract_t">Rhodes JM, Bartholomew TC, Jewell DP. Inhibition of leucocyte motility by drugs used in ulcerative colitis. Gut 1981; 22:642.</a></li><li><a class="nounderline abstract_t">Neal TM, Winterbourn CC, Vissers MC. Inhibition of neutrophil degranulation and superoxide production by sulfasalazine. Comparison with 5-aminosalicylic acid, sulfapyridine and olsalazine. Biochem Pharmacol 1987; 36:2765.</a></li><li><a class="nounderline abstract_t">Rubinstein A, Das KM, Melamed J, Murphy RA. Comparative analysis of systemic immunological parameters in ulcerative colitis and idiopathic proctitis: effects of sulfasalazine in vivo and in vitro. Clin Exp Immunol 1978; 33:217.</a></li><li><a class="nounderline abstract_t">Gadangi P, Longaker M, Naime D, et al. The anti-inflammatory mechanism of sulfasalazine is related to adenosine release at inflamed sites. J Immunol 1996; 156:1937.</a></li><li><a class="nounderline abstract_t">Box SA, Pullar T. Sulphasalazine in the treatment of rheumatoid arthritis. Br J Rheumatol 1997; 36:382.</a></li><li class="breakAll">Dougados M. Sulfasalazine. In: Therapy of Systemic Rheumatic Disorders, van de Putte LBA, Furst DE, Williams HJ, van Riel PLCM (Eds), Marcel Dekker, New York 1998. p.165.</li><li class="breakAll">Sulfasalazine https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/007073s130lbl.pdf (Accessed on November 03, 2021).</li><li class="breakAll">Azulfidine, EN-Tabs. In: Physicians Desk Reference, 52nd ed, Medical Economics Company, Montvale, NJ 1998. p.2239.</li><li><a class="nounderline abstract_t">Jacobson IM, Kelsey PB, Blyden GT, et al. Sulfasalazine-induced agranulocytosis. Am J Gastroenterol 1985; 80:118.</a></li><li><a class="nounderline abstract_t">Jick H, Myers MW, Dean AD. The risk of sulfasalazine- and mesalazine-associated blood disorders. Pharmacotherapy 1995; 15:176.</a></li><li><a class="nounderline abstract_t">Jansen G, van der Heijden J, Oerlemans R, et al. Sulfasalazine is a potent inhibitor of the reduced folate carrier: implications for combination therapies with methotrexate in rheumatoid arthritis. Arthritis Rheum 2004; 50:2130.</a></li><li><a class="nounderline abstract_t">Rao SS, Cann PA, Holdsworth CD. Clinical experience of the tolerance of mesalazine and olsalazine in patients intolerant of sulphasalazine. Scand J Gastroenterol 1987; 22:332.</a></li><li><a class="nounderline abstract_t">Giaffer MH, O'Brien CJ, Holdsworth CD. Clinical tolerance to three 5-aminosalicylic acid releasing preparations in patients with inflammatory bowel disease intolerant or allergic to sulphasalazine. Aliment Pharmacol Ther 1992; 6:51.</a></li><li><a class="nounderline abstract_t">Hanauer SB, Smith M. Critical drug appraisal: Olsalazine. Drug Ther Bull 1991; 21:57.</a></li><li><a class="nounderline abstract_t">Woltsche M, Woltsche-Kahr I, Roeger GM, et al. Sulfasalazine-induced extrinsic allergic alveolitis in a patient with psoriatic arthritis. Eur J Med Res 2001; 6:495.</a></li><li><a class="nounderline abstract_t">Coman RM, Glover SC, Gjymishka A. Febrile pleuropericarditis, a potentially life-threatening adverse event of balsalazide--case report and literature review of the side effects of 5-aminosalicylates. Expert Rev Clin Immunol 2014; 10:667.</a></li><li><a class="nounderline abstract_t">Adhiyaman V, Vaishnavi A, Froese S. Drug points: Hypersensitivity reaction to balsalazide. BMJ 2001; 323:489.</a></li><li class="breakAll">https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/204412s015lbl.pdf (Accessed on November 03, 2021).</li><li><a class="nounderline abstract_t">Gisbert JP, González-Lama Y, Maté J. 5-Aminosalicylates and renal function in inflammatory bowel disease: a systematic review. Inflamm Bowel Dis 2007; 13:629.</a></li><li><a class="nounderline abstract_t">World MJ, Stevens PE, Ashton MA, Rainford DJ. Mesalazine-associated interstitial nephritis. Nephrol Dial Transplant 1996; 11:614.</a></li><li><a class="nounderline abstract_t">Van Staa TP, Travis S, Leufkens HG, Logan RF. 5-aminosalicylic acids and the risk of renal disease: a large British epidemiologic study. Gastroenterology 2004; 126:1733.</a></li><li><a class="nounderline abstract_t">Bell CM, Habal FM. Safety of topical 5-aminosalicylic acid in pregnancy. Am J Gastroenterol 1997; 92:2201.</a></li><li><a class="nounderline abstract_t">Marteau P, Tennenbaum R, Elefant E, et al. Foetal outcome in women with inflammatory bowel disease treated during pregnancy with oral mesalazine microgranules. Aliment Pharmacol Ther 1998; 12:1101.</a></li></ol></div><div id="topicVersionRevision">Topic 4065 Version 32.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4402374" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : The role of intestinal bacteria in the metabolism of salicylazosulfapyridine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22914296" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Ulcerative colitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12492730" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Systematic review: the pharmacokinetic profiles of oral mesalazine formulations and mesalazine pro-drugs used in the management of ulcerative colitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16625536" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23076890" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22465970" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Can oral 5-aminosalicylic acid be administered once daily in the treatment of mild-to-moderate ulcerative colitis? A meta-analysis of randomized-controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22435504" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Once-daily versus multiple-daily mesalamine for patients with ulcerative colitis: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21894226" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Once-daily dosing vs. conventional dosing schedule of mesalamine and relapse of quiescent ulcerative colitis: systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16984503" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Once daily MMX mesalazine for the treatment of mild-to-moderate ulcerative colitis: a phase II, dose-ranging study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17234558" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Effect of once- or twice-daily MMX mesalamine (SPD476) for the induction of remission of mild to moderately active ulcerative colitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17241860" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Once-daily, high-concentration MMX mesalamine in active ulcerative colitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17593066" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : MMX Multi Matrix System mesalazine for the induction of remission in patients with mild-to-moderate ulcerative colitis: a combined analysis of two randomized, double-blind, placebo-controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15017487" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : A pilot feasibility study of once daily versus conventional dosing mesalamine for maintenance of ulcerative colitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20421464" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Peroxisome proliferator-activated receptor gamma activation is required for maintenance of innate antimicrobial immunity in the colon.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20848495" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Peroxisome proliferator-activated receptor-gamma (PPAR-γ) expression is downregulated in patients with active ulcerative colitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20848495" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Peroxisome proliferator-activated receptor-gamma (PPAR-γ) expression is downregulated in patients with active ulcerative colitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15824083" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Intestinal antiinflammatory effect of 5-aminosalicylic acid is dependent on peroxisome proliferator-activated receptor-gamma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Sulfasalazine inhibits cytokine production in human mononuclear cells: A novel anti-inflammatory mechanism</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1981213" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Sulfasalazine inhibits the binding of TNF alpha to its receptor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11151876" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Mesalazine inhibits activation of transcription factor NF-kappaB in inflamed mucosa of patients with ulcerative colitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30669" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Role of prostaglandins in ulcerative colitis. Enhanced production during active disease and inhibition by sulfasalazine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2866075" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Modulation of human colonic arachidonic acid metabolism by sulfasalazine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6114012" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Enhanced thromboxane A2 and prostacyclin production by cultured rectal mucosa in ulcerative colitis and its inhibition by steroids and sulfasalazine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2300172" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Identification and isolation of a membrane protein necessary for leukotriene production.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6120182" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Sulfasalazine inhibits the synthesis of chemotactic lipids by neutrophils.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7905704" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Effects of zileuton, a new 5-lipoxygenase inhibitor, in experimentally induced colitis in rats.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8109828" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Preclinical and clinical activity of zileuton and A-78773.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1359745" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : 5-Lipoxygenase inhibitors for the treatment of inflammatory bowel disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2883067" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Actions of sulfasalazine and 5-aminosalicylic acid as reactive oxygen scavengers in the suppression of bile acid-induced increases in colonic epithelial cell loss and proliferative activity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1969825" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Clinical evidence supporting the radical scavenger mechanism of 5-aminosalicylic acid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2702889" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : 5-Aminosalicylic acid concentration in mucosal interstitium of cat small and large intestine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9352849" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Effects of mesalamine on the hsp72 stress response in rat IEC-18 intestinal epithelial cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7815356" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : 5-Aminosalicylic acid abrogates T-cell proliferation by blocking interleukin-2 production in peripheral blood mononuclear cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2562949" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Inhibition of antibody secretion by 5-aminosalicylic acid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6116649" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Inhibition of leucocyte motility by drugs used in ulcerative colitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2888463" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Inhibition of neutrophil degranulation and superoxide production by sulfasalazine. Comparison with 5-aminosalicylic acid, sulfapyridine and olsalazine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31252" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Comparative analysis of systemic immunological parameters in ulcerative colitis and idiopathic proctitis: effects of sulfasalazine in vivo and in vitro.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8596047" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : The anti-inflammatory mechanism of sulfasalazine is related to adenosine release at inflamed sites.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9133974" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Sulphasalazine in the treatment of rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9133974" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Sulphasalazine in the treatment of rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9133974" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Sulphasalazine in the treatment of rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9133974" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Sulphasalazine in the treatment of rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2857524" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Sulfasalazine-induced agranulocytosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7624265" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : The risk of sulfasalazine- and mesalazine-associated blood disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15248210" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Sulfasalazine is a potent inhibitor of the reduced folate carrier: implications for combination therapies with methotrexate in rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2884724" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Clinical experience of the tolerance of mesalazine and olsalazine in patients intolerant of sulphasalazine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1347468" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Clinical tolerance to three 5-aminosalicylic acid releasing preparations in patients with inflammatory bowel disease intolerant or allergic to sulphasalazine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Critical drug appraisal: Olsalazine</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11726310" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Sulfasalazine-induced extrinsic allergic alveolitis in a patient with psoriatic arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24689504" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Febrile pleuropericarditis, a potentially life-threatening adverse event of balsalazide--case report and literature review of the side effects of 5-aminosalicylates.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11532843" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Drug points: Hypersensitivity reaction to balsalazide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11532843" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Drug points: Hypersensitivity reaction to balsalazide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17243140" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : 5-Aminosalicylates and renal function in inflammatory bowel disease: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8671848" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Mesalazine-associated interstitial nephritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15188168" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : 5-aminosalicylic acids and the risk of renal disease: a large British epidemiologic study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9399752" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Safety of topical 5-aminosalicylic acid in pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9845399" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Foetal outcome in women with inflammatory bowel disease treated during pregnancy with oral mesalazine microgranules.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
